Eli Lilly and Company

Gm Global Technolgoy Operations, Inc.

Merck Patent Gmbh

Elan Corporation, Plc

Lilly Icos LLC

Gregory Alan Stephenson

Susan M Reutzel

John Richard Nichols

Eugene D Thorsett

James E Audia

Varghese John

Jeffrey S Nissen

Donald Paul Matthews

Jay S Tung

Thomas Edward Mabry

Philip Arthur Hipskind

David W Robertson

David T Wong

Lee H Latimer

Owen Brendan Wallace

Yanping Xu

Nancy June Snyder

James M Greene

Holly M Hankins

Prabhakar Kondaji Jadhav

Peter Biagio Anzeveno

Charles A Bunnell

Venkatesh Krishnan

Donald L Cummins

Kerry John Hartauer

Renhua Li

Jonathan Edward Green

Susan Marie Reutzel-Edens

Samuel Dean Larsen

David D Wirth

Neil R Anderson

David Mitchell

Hongqi Tian

Ashraf Saeed

Ray W Fuller

Alexei Pavlovych Krasutsky

Frank Brown, Jr

Benjamin Alan Diseroad

Michael Vincent Mullen

Martha A Kral

Arlette Faye Kreager

Robert Alan Forbes

Susan Marie Reutzel-Eden

Leonard Larry Junior Winneroski

The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof. 

4-aminobenzonitrile selective androgen receptor modulators

The present invention provides a compound, or a pharmaceutically acceptable salt or hydrate, and a pharmaceutical composition containing said compound, or a pharmaceutically acceptable salt or hydrate, useful as a Notch pathway signaling inhibitor for the treatment of cancer.

Notch pathway signaling inhibitor compound

The present invention relates to novel crystalline forms of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate and to pharmaceutical compositions containing said forms.

Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl) piperazin-1-yl]methanone phosphate

The present invention provides crystalline (N)-((S)-2-hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one, a crystalline anydrate and dihydrates thereof, compositions comprising (N)-((S)-2-hydroxy-3-methyl-butyryl)-1-(L-alaninyl)-(S)-1-amino-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-2-one, its crystalline anhydrate or dihydrate, and methods for using the same.

Lactam compound

A compound of structural formula (I), and pharmaceutically acceptable salts and solvates thereof, wherein the compound is in free drug particulate form, is disclosed.

Beta-carboline drug products

The present invention provides a process for producing cefaclor crystalline bulk material having a dissolution rate in a capsule of &gE;80% in water in 30 minutes. One process route includes reducing the water content of cefaclor dihydrates or bulk material containing cefaclor dihydrate to produce a cefaclor form having a water content &lE;2%. The cefaclor having the lower water content can then be rehydrated to a water content from 3.0 to 6.5% without adversely affecting the dissolution rate. An alternative process includes the addition of at least 0.05% of cefaclor related substances to inhibit conversion of the monohydate to the dihydate form.

Process for preparing pharmaceutical bulk material having uniform dissolution

The present invention provides the novel Dihydrate D 2-methyl-thieno-benzodiazepine and a formulation therefor.

Olanzapine dihydrate D

The present invention provides a process for preparing olanzapine and intermediates therefor.

Intermediates and process for preparing olanzapine

The invention provides Form II dirithromycin, a novel polymorph of dirithromycin. Also disclosed are the acetone, 1-butanol, 1-propanol, and 2-propanol solvates of dirithromycin, which provide an efficient means for preparing and isolating Form II. Processes for preparing and isolating Form II dirithromycin from these solvates or from Form I dirithromycin are provided. A process for obtaining Form II dirithromycin from non-solvated dirithromycin is also provided. Another aspect of the invention is an improved tablet containing Form II dirithromycin as the active ingredient.

Process for preparing crystal forms and solvates of dirithromycin

Form II Dirithromycin

The present invention provides (S)-norfluoxetine and pharmaceutically acceptable salts thereof capable of inhibiting the uptake of serotonin.

(S)-norfluoxetine in method of inhibiting serotonin uptake

An electric starting system for controlling the energization of an electric starting motor that is operative to crank an engine. An engine speed sensor is coupled to the engine and develops engine speed pulses, the frequency of which is a function of engine speed. The engine speed pulses are counted by a counter for constant durations of time. If the number of speed pulses counted for a constant duration of time exceeds a predetermined number of pulses the starting motor is deenergized. The system has a start switch and a time delay circuit for causing the cranking motor to be energized at a predetermined time delay period following closure of the start switch.

Electronic starting motor control having automatic disengagement and

Growing community of inventors

Fishers, IN, United States of America

Gregory Alan Stephenson